SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 11, 2018
HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|Delaware||0 - 27072||52-0845822|
|(state or other jurisdiction||(Commission||(I.R.S. Employer|
|of incorporation)||File Number)||(Identification No.)|
|2117 SW Highway 484, Ocala FL||34473|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (407) 839-0095
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.02. Termination of a Material Definitive Agreement.
On December 11, 2018, Hemispherx Biopharma, Inc. terminated its December 15, 2015 Equity Distribution Agreement with Chardan Capital Markets, LLC.
Item 9.01 Financial Statements and Exhibits.
|10.1||Chardan Equity Distribution Agreement Termination letter.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|HEMISPHERX BIOPHARMA, INC.|
|December 11, 2018||By:||/s/ Adam Pascale|
|Adam Pascale, CFO|